Literature DB >> 23233124

Z and E rotamers of N-formyl-1-bromo-4-hydroxy-3-methoxymorphinan-6-one and their interconversion as studied by 1H/13C NMR spectroscopy and quantum chemical calculations.

Agnieszka Sulima1, Kejun Cheng, Arthur E Jacobson, Kenner C Rice, Klaus Gawrisch, Yong-Sok Lee.   

Abstract

N-Formyl-1-bromo-4-hydroxy-3-methoxymorphinan-6-one (compound 2), an important intermediate in the NIH Opiate Total Synthesis, presumably exists as a mixture of two rotamers (Z and E) in both n class="Chemical">CHCl(3) and DMSO at room temperature due to the hindered rotation of its N-C18 bond in the amide moiety. By comparing the experimental (1)H and (13)C chemical shifts of a single rotamer and the mixture of compound 2 in CDCl(3) with the calculated chemical shifts of the geometry optimized Z and E rotamers utilizing density functional theory, the crystalline rotamer of compound 2 was characterized as having the E configuration. The energy barrier between the two rotamers was also determined with the temperature dependence of (1)H and (13)C NMR coalescence experiments, and then compared with that from the reaction path for the interconversion of the two rotamers calculated at the level of B3LYP/6-31G*. Detailed geometry of the ground state and the transition states of both rotamers are given and discussed.
Copyright © 2012 This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233124      PMCID: PMC3551572          DOI: 10.1002/mrc.3909

Source DB:  PubMed          Journal:  Magn Reson Chem        ISSN: 0749-1581            Impact factor:   2.447


  6 in total

1.  Liquid-structure forces and electrostatic modulation of biomolecular interactions in solution.

Authors:  Sergio A Hassan
Journal:  J Phys Chem B       Date:  2007-01-11       Impact factor: 2.991

2.  Remarks on GIAO-DFT predictions of 13C chemical shifts.

Authors:  Katarzyna Dybiec; Adam Gryff-Keller
Journal:  Magn Reson Chem       Date:  2009-01       Impact factor: 2.447

3.  Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone.

Authors:  I Iijima; J Minamikawa; A E Jacobson; A Brossi; K C Rice
Journal:  J Med Chem       Date:  1978-04       Impact factor: 7.446

4.  Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors?

Authors:  Y F Jacquet; W A Klee; K C Rice; I Iijima; J Minamikawa
Journal:  Science       Date:  1977-11-25       Impact factor: 47.728

5.  Solution structures of the prototypical 18 kDa translocator protein ligand, PK 11195, elucidated with 1H/13C NMR spectroscopy and quantum chemistry.

Authors:  Yong-Sok Lee; Fabrice G Siméon; Emmanuelle Briard; Victor W Pike
Journal:  ACS Chem Neurosci       Date:  2012-02-14       Impact factor: 4.418

6.  Identification of the transition states in the inversion of 1,4-benzodiazepines with the ab initio replica path method.

Authors:  Yong-Sok Lee; Victor W Pike; Milan Hodoscek
Journal:  J Phys Chem A       Date:  2008-01-30       Impact factor: 2.781

  6 in total
  3 in total

1.  Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.

Authors:  Phong M Truong; Sergio A Hassan; Yong-Sok Lee; Theresa A Kopajtic; Jonathan L Katz; Aaron M Chadderdon; John R Traynor; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Bioorg Med Chem       Date:  2017-03-01       Impact factor: 3.641

2.  Chromatographically separable rotamers of an unhindered amide.

Authors:  Mario Geffe; Lars Andernach; Oliver Trapp; Till Opatz
Journal:  Beilstein J Org Chem       Date:  2014-03-21       Impact factor: 2.883

3.  Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors.

Authors:  Yogesh A Sonawane; Yingmin Zhu; Jered C Garrison; Edward L Ezell; Muhammad Zahid; Xiaodong Cheng; Amarnath Natarajan
Journal:  ACS Med Chem Lett       Date:  2017-10-02       Impact factor: 4.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.